Last reviewed · How we verify
Omega 3 pentaenoic acid
At a glance
| Generic name | Omega 3 pentaenoic acid |
|---|---|
| Also known as | MAT9001 |
| Sponsor | Matinas BioPharma Nanotechnologies, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia (PHASE2)
- Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL (PHASE3)
- Intervention Study to Prevent Obesity in Sedentary 8 Year Old Swedish Children (NA)
- Study of Omega-3 Fatty Acids Regarding Ergogenic, Anti-inflammatory and Obesity Inhibitory Effects in 8 Year Old Children (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omega 3 pentaenoic acid CI brief — competitive landscape report
- Omega 3 pentaenoic acid updates RSS · CI watch RSS
- Matinas BioPharma Nanotechnologies, Inc. portfolio CI